Overview

• In the 72‑week ATTAIN‑2 trial of more than 1,600 adults with obesity plus type 2 diabetes, the highest dose of orforglipron produced 10.5% average weight loss versus 2.2% with placebo, with 9.6% when analyzing all randomized patients.
• Glycemic control improved as A1C fell by 1.3% to 1.8% across doses, and 75% on the top dose reached an A1C of 6.5% or lower; cardiovascular risk markers, including cholesterol, triglycerides and blood pressure, also improved.
• Gastrointestinal side effects were common and generally mild to moderate, with nausea in 36.4%, vomiting in 23.1% and diarrhea in 27.4% at the highest dose; about 10% discontinued for side effects and roughly 20% stopped for any reason, similar to placebo.
• Lilly said the results give it a complete clinical package to initiate global regulatory submissions for chronic weight management, noting that orforglipron is a once‑daily small‑molecule pill without fasting or water restrictions.
• The pill enters a competitive race with Novo Nordisk, whose oral Wegovy application is under FDA review with a decision expected by year‑end, as investors sent Lilly shares up about 4% following the announcement; findings were released via company statements and are pending peer review.